Last reviewed · How we verify

NCT05215197

Intracochlear Platelet-rich Fibrin Application in Cochlear Implantation

Recruiting now NA Last updated 27 December 2024
What this trial tests

NA trial testing intracochlear platelet rich fibrin administration in Hearing Loss, Sensorineural in 10 participants. Currently enrolling.

Timeline
31 January 2022
Primary endpoint
1 December 2025
20 December 2025

Quick facts

Lead sponsorPamukkale University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment10
Start date31 January 2022
Primary completion1 December 2025
Estimated completion20 December 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Pamukkale University

Who can join

Eligibility, any sex, with Hearing Loss, Sensorineural. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fibrosis due to surgical trauma is a common problem with cochlear implants. Fibrosis limits the effectiveness of implant and increases the power consumption. Our aim in this study is to benefit from the anti-inflammatory effects of autologous platelet-rich fibrin to reducing the fibrotic cascade.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hearing Loss, Sensorineural

Currently open trials in the same condition.

Other Pamukkale University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05215197.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing